Pfizer has experienced a total return loss of nearly -40% so far in 2023, largely due to downshifts in demand for COVID-19 vaccines and antiviral products.
Shareholders faced additional challenges, including a dilutive $43 billion deal for Seagen, a tornado destroying its North Carolina production plant, and trouble with its weight-loss drug development plan. Pfizer's stock is now trading at a significantly lower valuation compared to peers, making it an attractive long-term investment with a high 5.7% dividend yield.
Entradas
No hay comentarios:
Publicar un comentario